{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-005260","form_type":"8-K","ticker":null,"cik":"0001845459","company_name":"NKGen Biotech, Inc.","filed_at":"2026-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.515050+00:00","generated_at":"2026-05-16T09:56:18.623335+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NKGen Biotech adds $295K to AlpineBrook secured note, principal now $26.1M","bullets":["Amendment to secured promissory note increases principal by $295,000 to $26,135,106.","Interest on original $25,840,106 accrues from Jan 5, 2026; on additional $295,000 from Jan 12, 2026.","Lender is AlpineBrook Capital GP I Limited; borrows are NKGen Biotech and NKGen Operating Biotech.","All other terms of the January 5, 2026 note remain unchanged."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-005260","json":"https://secwatch.observer/filing/0001213900-26-005260.json","markdown":"https://secwatch.observer/filing/0001213900-26-005260.md","text":"https://secwatch.observer/filing/0001213900-26-005260.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026005260/0001213900-26-005260-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026005260/ea0272566-8k_nkgen.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T09:56:18.623335+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"db8e437f743cd2252819867569af5f7ad4601682","claim":"NKGen Biotech, Inc. amended Amendment with AlpineBrook Capital GP I Limited valued at $295,000 (effective 2026-01-12).","evidence_excerpt":"On January 12, 2026, NKGen Biotech, Inc., a Delaware corporation (the “ Company ”), and NKGen Operating Biotech, Inc., a Delaware corporation (together with the Company, the “ Borrowers ”), entered into an amendment (the “ Amendment ”) to that certain secured promissory note with AlpineBrook Capital GP I Limited (the “ Lender ”), dated January 5, 2026 (the “ Note ”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1845459/000121390026005260/0001213900-26-005260-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"AlpineBrook Capital GP I Limited"},{"label":"Value","value":"$295,000"},{"label":"Effective","value":"2026-01-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}